Positive First Trial of Enasidenib for AML [News in Brief]

The first clinical trial of the investigational drug enasidenib, which targets IDH2 mutations, suggests that it is safe and may improve survival in patients with relapsed or refractory acute myeloid leukemia. It induced responses in 40.3% of patients, yielding a median overall survival of 9.3 months.
Source: Cancer Discovery - Category: Cancer & Oncology Tags: News in Brief Source Type: research